Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2023-10-20
First, I'd like to ask a question with regards to the revenue base. I'm looking at the presentation, I see that there is a sequential increase in the revenue removing the r CDMO base of the previous contract which is Paxlovid . How do you see the revenues growing over the next two quarters and also in the next one year?
Next part is with regards to the CDMO . You've mentioned that one is going to be the animal API business that is going to come into place and the other is the agrochemical. Do you see that this is going to be a structural change in the company where you're going to be diversifying not only from a pharma -based thing and diversify into other revenue streams like agri and also alternative sectors?